Trials / Not Yet Recruiting
Not Yet RecruitingNCT06226363
Phase I Study of LNF1901 in Advanced Malignant Tumors
Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Initial Efficacy of LNF1901 in Advanced Malignant Tumors
- Status
- Not Yet Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 82 (estimated)
- Sponsor
- Shandong New Time Pharmaceutical Co., LTD · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a multicenter, open, phase I dose-escalation and dose-expansion study to evaluate the safety, tolerability, initial antitumor efficacy, PK and immunogenic characteristics of LNF1901 in patients with advanced malignancies.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LNF1901 Monoclonal Antibody Injection | LNF1901，7 dose groups:0.003mg/kg、0.03mg/kg、0.1mg/kg、0.3mg/kg、1mg/kg、2mg/kg、3mg/kg，IV, infusion time 60min±10min, Q3W, until disease progression or other reasons to stop treatment, the longest administration to 2 years, whichever occurs first. |
Timeline
- Start date
- 2024-02-01
- Primary completion
- 2025-02-01
- Completion
- 2027-02-01
- First posted
- 2024-01-26
- Last updated
- 2024-01-26
Source: ClinicalTrials.gov record NCT06226363. Inclusion in this directory is not an endorsement.